CD274 and triple-negative breast carcinoma: This finding aligns with results from phase 3 clinical trials, which have demonstrated improved survival outcomes when checkpoint blockade is added to chemotherapy regimens in patients with advanced PD-L1-positive triple-negative breast cancer (47).